Entering text into the input field will update the search result below

Agios Pharma's AG-348 shows treatment effect in mid-stage PK study, but proportion achieving max hemoglobin increase lower than previously reported; shares down 9%

Jun. 26, 2017 10:40 AM ETAgios Pharmaceuticals, Inc. (AGIO) StockBy: Douglas W. House, SA News Editor
  • Agios Pharmaceuticals (NASDAQ:AGIO -9%) slumps on slightly higher volume in response to its announcement of updated results from a Phase 2 clinical trial, DRIVE PK, assessing AG-348 for the treatment of patients with pyruvate kinase (PK) deficiency. The data were presented at the European Hematology Association Annual Meeting in Madrid.
  • As of the March 27 data cutoff, 48% (n=25/52) of all 52 treated patients experienced a maximum increase in hemoglobin (Hb) of greater than 1.0 g/dL from baseline. Data reported in December 2016 showed 58% (n=15/26) achieved the maximum increase in Hb. In May 2016, the percentage was 68% (n=13/19).
  • On the safety front, the most frequent mild/moderate adverse events (AEs) in the treatment group were headache, insomnia and nausea. Three patients discontinued treatment: chest discomfort/pleural effusion, pharyngitis/nausea and anemia. Five participants experienced serious AEs: withdrawal hemolysis followed by anemia (n=1), anemia (1), osteoporosis (1), hypertriglyceridemia (1) and pharyngitis (1).
  • PK is an enzyme that plays a key role in glycolysis, the conversion of glucose into lactic acid. PK has several tissue-specific isoforms (PKR, PKL, PKM1, PKM2). Inherited mutations in PKR enzymes cause a deficit in cellular energy within red blood cells which leads to the clinical manifestations of PK deficiency.
  • The rationale for AG-348, an oral activator of PKR, is the restoration of metabolic function and the correction of the underlying defect in red blood cells in PK deficiency sufferers.
  • The company intends to advance AG-348 into Phase 3 development in H1 2018.

Recommended For You

More Trending News

About AGIO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AGIO--
Agios Pharmaceuticals, Inc.